Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 90

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 90
---
495                                                                                        |

| 2. | DrugBank                                                                     
 Online: Mupirocin (DB00410). DrugBank. https://go.drugbank.com/drugs/DB00410 |

| 3. | Kulkarni                                                                                                                                  
 NS, et al. Therapeutic potential of injectable nano-mupirocin liposomes against MRSA and VRE infections. Pharmaceutics. 2021;13(11):1789. 
 PMC8706398                                                                                                                                |

| 4. | He W,                                                                                                                         
 et al. Enhanced uptake of antibiotic-loaded nanoparticles by macrophages improves intracellular killing of pathogens. Journal 
 of Controlled Release. 2021;336:149–162.                                                                                      |

| 5. | WHO. WHO Bacterial Priority                                                 
 Pathogens List, 2024. https://www.who.int/publications/i/item/9789240093461 |

| 6. | Cern A,                                                                                                                                        
 Connolly KL, Jerse AE, Barenholz Y. In Vitro Susceptibility of Neisseria gonorrhoeae Strains to Mupirocin, an Antibiotic Reformulated          
 for Parenteral Administration in Nanoliposomes. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02377-17. https://doi.org/10.1128/aac.02377-17 |

| 7. | O. Goldmann,                                                                                                                        
 A. Cern, M. Muesken, et al., Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections, 
 Journal of Controlled Release (2019), https://doi.org/10.1016/j.jconrel.2019.11.007                                                 |

<div align='center'>56</div>

IP protection.

Several patents and licenses for Nano-Mupirocin
were already obtained in major countries and regions, including the U.S., Europe (in the table referred to as European Patent Office
– EP), Japan, India and China.

Pursuant to the Yissum License Agreements, we
have an exclusive, worldwide license for the development, use, manufacture and commercialization of products arising out of patents owned
by, and patent applications filed by, Yissum in connection with Liposomal formulation of Nano-Mupirocin. All of patents and patent applications
listed below were licensed to us by Yissum pursuant to